Archive: 03/12/2018
New study highlights CAR T-cell therapy success for lymphoma when used as standard of care
Chimeric antigen receptor T-cell therapy, or CAR T, was named the 2017 Advance of the Year by the American Society of Clinical Oncology. The FDA approved two CAR T products last year for treatment of adult large B-cell lymphoma ...
Dec 3, 2018
Dana-Farber researchers report clinical trial results in treatment of leukemia and lymphoma
New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the American Society of Hematology ...
Dec 3, 2018
New two-year data show 39 percent of NHL patients treated with CAR T remain in remission
A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy (CAR T) Yescarta (axicabtagene ciloleucel) remained in remission ...
Dec 3, 2018